Ariad axes 90 staffers in ongoing reorg

Cambridge, MA-based Ariad Pharmaceuticals ($ARIA) is axing about 90 staffers--25% of its total workforce--in an ongoing restructuring of the business. The biotech is also reviewing its R&D portfolio and other aspects of the business, saying it plans to unveil more changes in Q2. Ariad says it is concentrating efforts around its once-suspended cancer drug Iclusig as well as the late-stage drug brigantinib. Brigantinib, its only other clinical asset, is in pivotal studies for non-small cell lung cancer. Ariad laid off 40% of its staff in 2013 when it was forced to yank its leukemia drug off the market. Release

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.